AstraZeneca Gives FDA More Data On Brilinta Interaction With High-Dose Aspirin
This article was originally published in The Pink Sheet Daily
Executive Summary
In replying to FDA's December "complete response," company reaffirms its view that U.S. efficacy in the pivotal PLATO study was undercut by high doses of concomitant aspirin.
You may also be interested in...
Brilinta Approval Shows AstraZeneca's Success With Aspirin Theory, But Can It Change The Market?
FDA appears to have come around to the "aspirin hypothesis" offered by AstraZeneca PLC to explain poor results for North American patients who took the blood-thinner Brilinta, though labeling takes a somewhat cautious approach that reflects initial concerns about that explanation.
Brilinta Approval Shows AstraZeneca's Success With Aspirin Theory, But Can It Change The Market?
FDA appears to have come around to the "aspirin hypothesis" offered by AstraZeneca PLC to explain poor results for North American patients who took the blood-thinner Brilinta, though labeling takes a somewhat cautious approach that reflects initial concerns about that explanation.
AstraZeneca's Brilique Cleared In NICE's Initial Appraisal
The U.K.'s cost regulator, NICE, clears AstraZeneca's antiplatelet drug ticagrelor for use in the National Health Service in a preliminary assessment.